Delin Ventures
VC Fund
London, United Kingdom
Delin Ventures is a VC fund in London focused on Software and Biotechnology. We invest in early stage technology businesses and, in exceptional cases, will create them from scratch with outstanding partners. We pride ourselves on being open minded and ready to support ideas orthogonal to consensus views.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Delin Ventures invests in
Stages Delin Ventures invests in
Countries Delin Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $1.3M–$9.2M
- Series A
- $5.1M–$30M
- Series B
- $16M–$100M
Investment Focus
Industry
- Software 6 (18%)
- Biotechnology 5 (15%)
- Information Technology 4 (12%)
- Life Science 3 (9%)
- EdTech 2 (6%)
Stage
- Seed 17 (52%)
- Series A 7 (21%)
- Series B 2 (6%)
- Series C 1 (3%)
- Funding Round 1 (3%)
Country
- United Kingdom 16 (48%)
- Germany 1 (3%)
- Hungary 1 (3%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alan Barge
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Igor Linshits
Founder
|
Founder | Total investments: 0 | Find email | |
Martina Lubrano di Ricco
Investment Associate
|
Investment Associate | Total investments: 0 | Find email | |
Nick Coleman
Financial Director
|
Financial Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Swarm Oncology
|
Swarm Oncology is a biotechnology company that develops novel T cell therapies for cancer patients. | $8.1M / Seed / Mar 05, 2026 | |
Penzilla
|
At Penzilla, we believe it's time to make corporate pension provision the way it really should be - simple. That's why we offer a solution that helps everyone get the maximum benefit from corporate pension options. Most importantly, we enable every employer to achieve true corporate social responsibility with 100% compliance and everyemployee to receive a fair pension. This is how corporate pension provision works with Penzilla: Let's "Simply Provision" together. | $3.6M / Seed / May 14, 2025 | |
Umedeor
|
uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams | $12.8M / Series A / Jul 05, 2023 | |
Turbine
|
Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $20.6M / Series A / Nov 22, 2022 | |
|
Turbine
|
Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $20.6M / Series A / Nov 22, 2022 | |
Ori Biotech
|
Ori Biotech is a developer of a manufacturing platform used to help patients get access to lifesaving treatments. Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process developmentto commercial-scale manufacturing. The company aims to speed up the innovation of cell and gene therapies through the manufacturing platform it is bringing to market. | $100M / Series B / Jan 18, 2022 | |
Vidsy
|
Vidsy is a creative technology engine powering mobile video ad creation to help global brands. Vidsy helps global brands create effective video ads, efficiently and consistently across digital. Vidsy's technology, global community of 6,000+ vetted creators, and fully managed services are empowering brands to intelligently transform theirdigital advertising for an ever-evolving world of mobile video. | $16.3M / Series B / Oct 11, 2021 | |
Onsi
|
Onsi provides an easy way for businesses to reward their workers. Our platform is designed to help businesses build programmes that drive loyalty and engagement, delivering a wide range of benefits to workers via their Onsi Card. For businesses, it’s all about getting the right results through tiering and gamification. For workers, it’s all aboutmeaningful benefits they can use every day to improve their financial lives. | $8.3M / Series A / Jul 14, 2021 | |
Agile Analog
|
Agile Analog is a company with a mission to transform the landscape of the Analog IP market space. | $19M / Series A / May 17, 2021 | |
|
Turbine
|
Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $6M / Series A / Jan 07, 2021 | |
| See all 33 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Delin Ventures invest in?
Delin Ventures invests primarily in Software, Biotechnology and Information Technology startups, most often at Seed and Series A stage. Most of the 33 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Delin Ventures's check size?
Delin Ventures typically joins rounds of $1.3M–$9.2M at Seed, $5.1M–$30M at Series A and $16M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Delin Ventures participates in.
How do I contact Delin Ventures?
Public channels for Delin Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Delin Ventures?
The team at Delin Ventures includes Alan Barge (Venture Partner), Igor Linshits (Founder) and Martina Lubrano di Ricco (Investment Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
